Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. - Wikidata - wikimedia - TriplyDB

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

http://www.wikidata.org/entity/Q34943606

about

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients Shared Risk Factors in Cardiovascular Disease and Cancer.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.Renal Toxicities of Targeted Therapies.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease.Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.The therapeutic potential of HIF-2 antagonism in renal cell carcinoma.Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report.Renin angiotensin system deregulation as renal cancer risk factor.Use of Antihypertensive Drugs in Neoplastic Patients.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.Cardiovascular toxic effects of targeted cancer therapy.Hypertension in malignancy-an underappreciated problem.Treatment effect of conversion therapy and its correlation with VEGF expression in unresectable rectal cancer with liver metastasis.Research progress on common adverse events caused by targeted therapy for colorectal cancer.

P2860

Q26751341-A14D8B00-FE0E-4A3D-ADC8-94D8650A8D77 Q26765210-98E86D1A-5342-4D23-8B50-59D32287AC3A Q28066747-F704EC27-BBFD-4EE3-AF20-5CEE2E46E2B7 Q28080163-7EDE3FC7-8E1D-4A53-9634-CA3AF7297095 Q36709155-0E389410-C401-44E5-9AF1-4BC928773BFA Q36755620-B2ECA381-EBC9-47E1-8795-991EB6E220D6 Q37215966-942AA1F5-BDEE-4226-B8A9-FD03674DFCA8 Q37737863-AB2106A1-9157-4489-B8E6-D07DA00D35D2 Q38406251-DA0D8B1C-5E8B-437A-A179-EC60614FD11F Q38448007-5155656D-616F-4449-84BE-5EC3F915D453 Q38501976-1E7D0574-CF2F-4AB3-875F-4098C3F39DAB Q38546217-D6C37194-555E-4842-8F97-8A8B568E10E7 Q38754136-268E6FA7-D665-4F08-A3AC-433AE24C2FC0 Q39171512-51F61109-06C3-43DF-AA68-6A364D372B54 Q39384416-C9049F98-9169-4E89-9AEA-A2D8519388B3 Q40336236-A36EE6B6-8D3A-4C68-BF80-FD695CD4E113 Q41035635-5C2EDD18-8BA0-4D79-92A4-8489E2CE0CE8 Q42320961-25E4B015-43CA-4568-B53F-2128CF804043 Q42336244-512902C5-8646-4CA1-A6BD-11B688A9731E Q44096551-3F281F56-1066-4969-997C-E5BBA9630F18 Q45980261-14DD747D-E028-4A07-9719-01F54B295823 Q47094986-676934A3-4C6E-4865-AED1-04B30E57C50C Q48342585-AEFDF4DE-8C05-44A2-9E45-384D4868D777 Q49635743-C5269ADA-EC23-4C6A-B5E5-AE8D6038DF97 Q50204127-7FD09F48-BC6E-4690-9B9E-4E3CF53FFB9D Q50350183-5B744B4A-DE13-42E3-817B-BE08B3955EBA Q50512896-6C46E0E6-CF4A-4EE4-A956-CE4A49955897 Q52808495-6C3338F4-E7EC-470E-A039-99DBDB3C4C79 Q53276936-97D74A9C-306B-4412-9AF2-9D9BC084D45B Q55071881-EECC6658-9B0F-446C-AD5E-D1211B561094 Q55359283-162397F8-C684-493B-9337-E73F13F1EC1E Q55360813-3E2F912D-6FC5-49DF-B9D3-C30177E88D1E

P2860

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

http://www.wikidata.org/entity/Q34943606

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical risk factors for the ...... of the VEGF signaling pathway.

@ast

Clinical risk factors for the ...... of the VEGF signaling pathway.

@en

Clinical risk factors for the ...... of the VEGF signaling pathway.

@nl

type

label

Clinical risk factors for the ...... of the VEGF signaling pathway.

@ast

Clinical risk factors for the ...... of the VEGF signaling pathway.

@en

Clinical risk factors for the ...... of the VEGF signaling pathway.

@nl

prefLabel

Clinical risk factors for the ...... of the VEGF signaling pathway.

@ast

Clinical risk factors for the ...... of the VEGF signaling pathway.

@en

Clinical risk factors for the ...... of the VEGF signaling pathway.

@nl

P1433

Q34943606-8B238DD0-5214-4CE4-8DF1-340DAEDEB350

P1476

Q34943606-561D10C9-C742-497C-A13E-B8298A124A09

P2093

Q34943606-2DC0C3B4-A3B7-4665-95CE-33A07BB30D32

Q34943606-42BF159C-2D2F-4EB2-A659-BA4FB02E7A17

Q34943606-44BB6123-D816-41AA-A5AF-52363BAE09A2

Q34943606-4936E98F-8180-42B4-827B-CB983D55324B

Q34943606-5E6A1182-FB6F-4CE1-AA80-C4C9DC915FEC

Q34943606-D122A36A-AADF-4E86-BED4-E68C8B960094

P2860

Q34943606-019BF169-E73D-43F7-9022-62E7B4F2A388

Q34943606-09D2B90A-325A-4307-BAD5-92F9DE882AC6

Q34943606-1B34F46D-1726-49D6-9315-3F2E85B34A8D

Q34943606-28A816CC-963B-4E4B-8746-B9CBF2955B89

Q34943606-49E86758-FB43-4A0F-9F80-6929D6C424A0

Q34943606-509EE547-07EF-452A-94D4-62E88C80FB4A

Q34943606-51DCC195-1DC8-40A2-82DE-298639C0EF23

Q34943606-57F75285-90C6-4F65-8A9F-4AA1BD6D4498

Q34943606-5E4891C8-0322-4731-A36B-26FFF7EF7BB6

Q34943606-5E8B742E-2673-42F7-9090-B1CDF5D821B6

P304

Q34943606-88245338-0AE1-4C39-A681-D8AC9E4B6863

P31

Q34943606-65C20DEF-B66F-47B9-BBCC-2650D369E3E7

P356

Q34943606-5726B2AE-474E-4FF1-8C4B-23267F8B0BA6

P407

Q34943606-AF87FC40-5591-4B69-AB8F-2C43B3263BB8

P433

Q34943606-D1BECCC3-42D1-4FCE-8BB4-D89C3E35EBCB

P478

Q34943606-14975A7A-DA0A-4EA6-80B6-A73F45FEF731

P50

Q34943606-A5D6BCC6-81E7-402D-A1E8-E2D09AD4E918

Q34943606-E73B2797-757B-45F9-AD5F-BF75386BECD3

P577

Q34943606-2D6C6108-4EFE-4F6E-B07F-25AAE599366F

P698

Q34943606-1AA8173D-D9BB-46CC-A40C-169C29F18900

P921

Q34943606-FC26B227-287C-4CA1-AFBE-4EBB92C04FB6

P932

Q34943606-1A856EC4-D855-4212-8525-B988477F1B09

P356

P1433

P1476

Clinical risk factors for the ...... of the VEGF signaling pathway

@en

P2093

Alexander Turchin

http://www.w3.org/2001/XMLSchema#string

Lipika Goyal

http://www.w3.org/2001/XMLSchema#string

Marina D Kaymakcalan

http://www.w3.org/2001/XMLSchema#string

Michael Davis

http://www.w3.org/2001/XMLSchema#string

Rana R McKay

http://www.w3.org/2001/XMLSchema#string

Toni K Choueiri

http://www.w3.org/2001/XMLSchema#string

P2860

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

Sorafenib in advanced hepatocellular carcinoma

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination

Differences between clinical trials and postmarketing use.

Anti-VEGF therapies in the clinic

P304

311-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28972

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Williams

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25236375

http://www.w3.org/2001/XMLSchema#string

P921

P932

4293233

http://www.w3.org/2001/XMLSchema#string